What to Watch at DexCom, Smith & Nephew, and Endo Health Solutions This Morning

DexCom, Smith & Nephew, and Endo Health Solutions could be big health care stories this morning. Read on to find out why.

Feb 4, 2014 at 8:57AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! Let's take a look at three stocks -- DexCom (NASDAQ:DXCM), Endo Health Solutions (NASDAQ:ENDP), and Smith & Nephew (NYSE:SNN) -- which could loom large in health care headlines this morning.

The FDA approves DexCom's CGM device for children
Medical device maker DexCom looks poised to open higher this morning, after the FDA approved the DexCom G4 Platinum (Pediatric), its new CGM (continuous glucose monitoring) device designed for children ages 2 to 17 with diabetes. The device is now the only approved CGM device for children as young as two years old, and had previously been approved for adults 18 years and older.

DexCom's device has a 20-foot wireless transmission range, a lightweight receiver which weighs 2.4 ounces, and easy to wear transmitters which are placed on the abdomen and upper buttocks. It is also the only sensor on the market which can be worn for up to seven days.

Last quarter, DexCom's product revenues, which are generated by sales of the CGM systems and the disposable sensors, rose 101% year-over-year to $42.5 million. The company is still unprofitable, but it narrowed its loss to $0.08 per share last quarter, up from a loss of $0.25 per share a year earlier.

In addition to its core products, DexCom also holds collaboration agreements with Animas (a subsidiary of Johnson & Johnson) and Tandem Diabetes Care. The Animas collaboration aims to create a new wearable artificial pancreas to rival Medtronic's first generation device, which was approved last September.

The newly approved pediatric CGM device should boost DexCom's revenue in the coming year, since diabetes remains one of the most common chronic diseases in children in the United States, affecting 151,000 people below the age of 20, according to the CDC.

Endo divests one business while acquiring another
Meanwhile, Endo Health Solutions wrapped up two deals -- the divestment of HealthTronics and the acquisition of Boca Pharmacal.

Endo completed the previously announced divestiture of HealthTronics, a provider of urologic services and products, to Altaris Capital Partners for an upfront cash payment of $85 million. Endo also received the rights to additional cash payments of up to $45 million, dependent on the future performance of HealthTronics under Altaris for a maximum consideration of $130 million.

Endo originally acquired HealthTronics for $223 million in 2010, so selling the unit for a maximum of $130 million isn't exactly a good deal. However, it could help Endo, which generated 21% of its revenue from the Lidoderm painkiller patch last quarter, streamline its operations to focus on its other pain medications (Opana ER, Voltaren Gel, and Percocet) instead.

Endo then announced that its Qualitest subsidiary had completed the acquisition of privately held Boca Pharmacal, a specialty pharmaceutical company focusing on controlled substances, semisolids, and solutions. The deal, which was made for $225 million in cash, is expected to enhance Qualitest's R&D pipeline of controlled substance generics.

Last quarter, Endo's earnings fell 25.2% year-over-year as its revenue fell 4.7%. Both deals could help boost its top and bottom line growth by streamlining its product portfolio.

Will Smith & Nephew make a higher offer for ArthroCare?
Last but not least, investors should also keep an eye on medical device maker Smith & Nephew, which agreed to acquire ArthroCare (NASDAQ:ARTC) for $1.7 billion in cash yesterday. ArthroCare is a maker of minimally invasive surgical products used primarily for sports medicine.

Some investors are skeptical that the deal will close at the currently offered price of $48.25 per share, which only represents a 6.3% premium over ArthroCare's closing price on January 31. After the announcement, shares of ArthroCare closed at $49.12, indicating that investors might be expecting Smith & Nephew to place a higher offer.

There are three reasons for this belief:

  • Price targets for ArthroCare are considerably higher than $48.25. Analysts at Canaccord Genuity and Craig-Hallum Capital currently have price targets of $56.00 and $60.00 for the stock.

  • The stock hit an intraday high of $49.95 on January 8, 2014.

  • ArthroCare is financially healthy. Last quarter, the company's total revenue rose 5.7% year-over-year to $91.9 million as its gross profit climbed 3.8% to $63.0 million.

Therefore, even though Smith & Nephew has agreed to those terms, the deal could still be rejected by ArthroCare shareholders.

Smith & Nephew has slightly lagged its main rival, Stryker, since the beginning of the year.


Qty. Earnings Growth (YOY)

Qty Revenue Growth


Profit Margin

YTD Price Performance

Smith & Nephew










Source: Yahoo Finance, Feb. 4.

Smith & Nephew believes that cost reduction and additional sales from the ArthroCare acquisition will boost its annual profit by roughly $85 million in the third full year after deal closes.

It could also help diversify its product portfolio beyond the surgical and wound management products that account for the majority of its top line.

Another top stock to watch this morning
Tired of market volatility? The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information